Amgen Statement On Government Budget Analysis For Oral-Only Treatments For
THOUSAND OAKS, Calif., Feb. 22, 2013
THOUSAND OAKS, Calif., Feb. 22, 2013 /PRNewswire/ --Amgen (NASDAQ:AMGN) notes
that an analysis by the Congressional Budget Office released this week shows
that, contrary to the implications of past media reports, keeping oral-only
drugs in Medicare Part D would actually achieve significant savings over time
for both taxpayers and the Medicare program.
As noted by the Government Accountability Office (GAO), it is important that
the Centers for Medicare and Medicaid Services (CMS) take the time needed to
develop quality metrics and further developtheir data systems, both of which
are essential to providing quality care for an elderly and chronically ill
Amgen will continue to advocate for sound federal policies that enhance access
to care for these patients.
For more background, please visit Our Perspectives on www.amgen.com.
CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)
Press spacebar to pause and continue. Press esc to stop.